Dalteparin (Fragmin) to prevent clotting during hemodialysis
https://libcat.nshealth.ca/en/permalink/chpams35807
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1760
- Available Online
- View Pamphlet
Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Dalteparin
- Renal Dialysis
- Subjects (LCSH)
- Hemodialysis
- Blood--coagulation
- Specialty
- Nephrology
- Abstract
- Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1760
Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke
https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 2217
- Available Online
- View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([2] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Anemia - drug therapy
- Hematinics - therapeutic use
- Neoplasms
- Stroke
- Subjects (LCSH)
- Chronic renal failure--Complications
- Hematopoietic growth factors
- Renal anemia--Chemotherapy
- Cancer
- Cerebrovascular disease
- Abstract
- Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 2217
Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1493
- Available Online
- View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Anemia - drug therapy
- Hematinics - therapeutic use
- Subjects (LCSH)
- Chronic renal failure--Complications
- Hematopoietic growth factors
- Renal anemia--Chemotherapy
- Abstract
- Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1493
